NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com began coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Monday morning. The brokerage issued a hold rating on the stock.

NovaBay Pharmaceuticals Stock Performance

NYSE:NBY opened at $0.64 on Monday. The firm has a market cap of $3.41 million, a PE ratio of -0.01 and a beta of 0.73. NovaBay Pharmaceuticals has a fifty-two week low of $0.36 and a fifty-two week high of $9.08. The business has a 50 day moving average price of $0.66 and a 200-day moving average price of $0.63.

About NovaBay Pharmaceuticals

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.